Association of anhedonia and suicidal ideation in patients with treatment-refractory depression after intravenous ketamine infusions.

Wei Zheng, Li-Mei Gu, Xin-Hu Yang, Yan-Ling Zhou, Cheng-Yu Wang, Xiao-Feng Lan, Bin Zhang, Yu-Ping Ning
{"title":"Association of anhedonia and suicidal ideation in patients with treatment-refractory depression after intravenous ketamine infusions.","authors":"Wei Zheng,&nbsp;Li-Mei Gu,&nbsp;Xin-Hu Yang,&nbsp;Yan-Ling Zhou,&nbsp;Cheng-Yu Wang,&nbsp;Xiao-Feng Lan,&nbsp;Bin Zhang,&nbsp;Yu-Ping Ning","doi":"10.1080/13651501.2022.2138444","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Accumulating evidence suggests that the effects of ketamine administered intravenously at subanaesthetic doses on both anhedonic symptoms and suicidal ideation occur independently of depressive symptoms in major depressive disorder (MDD) and bipolar disorder (BD). This study sought to determine the relationship between anhedonia and suicidal ideation after serial ketamine infusions.</p><p><strong>Methods: </strong>A total of 79 subjects with either treatment-refractory MDD (<i>n</i> = 60) or BD (<i>n</i> = 19) were included in a clinical ketamine study. The Montgomery-Åsberg Depression Rating Scale (MADRS) anhedonia factor and the first five items of the Scale for Suicidal Ideations (SSI-Part I) were used to assess anhedonia symptoms and suicidal ideation, respectively.</p><p><strong>Results: </strong>At baseline, anhedonia, as measured by the MADRS, was not significantly associated with suicidal ideation or specific suicide-related ideation as measured by SSI-Part I (all <i>p</i>'s > 0.05). Only the 'wish to die' and 'desire to make a suicide attempt' items were positively associated with anhedonia at two weeks after the sixth ketamine infusion, which was independent of the reductions in depressive symptoms (all <i>p</i>'s < 0.05).</p><p><strong>Conclusion: </strong>Anhedonia as measured by the MADRS appeared to not be positively related to suicidal ideation after serial ketamine infusions.KEY POINTSSerial ketamine (0.5 mg/kg) infusions have shown quick and dramatic antisuicidal and antianhedonic effects in patients with depression.The association between anhedonia and suicidal ideation after serial ketamine infusions is unclear.Anhedonia appeared to not be positively related to suicidal ideation after serial ketamine infusions.</p>","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Psychiatry in Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13651501.2022.2138444","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Accumulating evidence suggests that the effects of ketamine administered intravenously at subanaesthetic doses on both anhedonic symptoms and suicidal ideation occur independently of depressive symptoms in major depressive disorder (MDD) and bipolar disorder (BD). This study sought to determine the relationship between anhedonia and suicidal ideation after serial ketamine infusions.

Methods: A total of 79 subjects with either treatment-refractory MDD (n = 60) or BD (n = 19) were included in a clinical ketamine study. The Montgomery-Åsberg Depression Rating Scale (MADRS) anhedonia factor and the first five items of the Scale for Suicidal Ideations (SSI-Part I) were used to assess anhedonia symptoms and suicidal ideation, respectively.

Results: At baseline, anhedonia, as measured by the MADRS, was not significantly associated with suicidal ideation or specific suicide-related ideation as measured by SSI-Part I (all p's > 0.05). Only the 'wish to die' and 'desire to make a suicide attempt' items were positively associated with anhedonia at two weeks after the sixth ketamine infusion, which was independent of the reductions in depressive symptoms (all p's < 0.05).

Conclusion: Anhedonia as measured by the MADRS appeared to not be positively related to suicidal ideation after serial ketamine infusions.KEY POINTSSerial ketamine (0.5 mg/kg) infusions have shown quick and dramatic antisuicidal and antianhedonic effects in patients with depression.The association between anhedonia and suicidal ideation after serial ketamine infusions is unclear.Anhedonia appeared to not be positively related to suicidal ideation after serial ketamine infusions.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
难治性抑郁症患者静脉注射氯胺酮后快感缺乏与自杀意念的关系。
目的:越来越多的证据表明,在重度抑郁症(MDD)和双相情感障碍(BD)中,静脉注射亚麻醉剂量氯胺酮对快感缺乏症状和自杀意念的影响独立于抑郁症状发生。本研究旨在确定连续氯胺酮输注后快感缺乏与自杀意念之间的关系。方法:共79例难治性重度抑郁症(n = 60)或重度抑郁症(n = 19)纳入氯胺酮临床研究。采用Montgomery-Åsberg抑郁评定量表(MADRS)快感缺乏因素和自杀意念量表(SSI-Part I)前5项分别评估快感缺乏症状和自杀意念。结果:在基线时,MADRS测量的快感缺乏与自杀意念或SSI-Part I测量的特定自杀相关意念无显著相关(均p > 0.05)。在第六次氯胺酮输注后的两周内,只有“想死”和“想自杀”与快感缺乏症呈正相关,这与抑郁症状的减轻无关(所有p的结论:MADRS测量的快感缺乏症似乎与连续输注氯胺酮后的自杀意念没有正相关)。连续输注氯胺酮(0.5 mg/kg)在抑郁症患者中显示出快速和显著的抗自杀和抗快感缺乏作用。连续氯胺酮输注后快感缺乏与自杀意念之间的关系尚不清楚。在连续注射氯胺酮后,快感缺乏似乎与自杀意念没有正相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.00
自引率
3.30%
发文量
42
审稿时长
>12 weeks
期刊介绍: International Journal of Psychiatry in Clinical Practice provides an international forum for communication among health professionals with clinical, academic and research interests in psychiatry. The journal gives particular emphasis to papers that integrate the findings of academic research into realities of clinical practice. Focus on the practical aspects of managing and treating patients. Essential reading for the busy psychiatrist, trainee and interested physician. Includes original research papers, comprehensive review articles and short communications. Key words: Psychiatry, Neuropsychopharmacology, Mental health, Neuropsychiatry, Clinical Neurophysiology, Psychophysiology, Psychotherapy, Addiction, Schizophrenia, Depression, Bipolar Disorders and Anxiety.
期刊最新文献
Mirtazapine blood levels and antidepressant response. Exploring real-world prescribing patterns for maintenance treatment in bipolar disorders: a focus on antidepressants and benzodiazepines. Real-world demographic and clinical profiles of patients with treatment-resistant depression initiated on esketamine nasal spray. Real-world outcomes of long-term use of silexan in patients with anxiety disorders: a single-centre experience. Neurobiological and psychological factors to depression.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1